A Modified Post-Transplant Cyclophosphamide Regimen, for Unmanipulated Haploidentical Marrow Transplantation, in Acute Myeloid Leukemia: A Multicenter Study

P. Chiusolo; G. Bug; A. Olivieri; M. Brune; N. Mordini; P.E. Alessandrino; A. Dominietto; A.M. Raiola; C. Di Grazia; F. Gualandi; M.T. Van Lint; F. Ferrara; O. Finizio; E. Angelucci; A. Bacigalupo

doi:10.1016/j.bbmt.2018.01.031

A Modified Post-Transplant Cyclophosphamide Regimen, for Unmanipulated Haploidentical Marrow Transplantation, in Acute Myeloid Leukemia: A Multicenter Study

P. Chiusolo, G. Bug, A. Olivieri, M. Brune, N. Mordini, P.E. Alessandrino, A. Dominietto, A.M. Raiola, C. Di Grazia, F. Gualandi, M.T. Van Lint, F. Ferrara, O. Finizio, E. Angelucci, A. Bacigalupo

IRCCS Fondazione Policlinico Universitario A. Gemelli

Research output: Contribution to journal › Article › peer-review

Abstract

We report a modified post-transplant cyclophosphamide (PT-CY) regimen, for unmanipulated haploidentical marrow transplants, in 150 patients with acute myeloid leukemia (AML). All patients received a myeloablative regimen, cyclosporine A (CsA) on day 0, mycophenolate on day +1, and PT-CY 50 mg/kg on days +3 and +5. The median age was 51 (range, 17–74) years, 51 (34%) patients had active disease at transplant, and the median follow-up of surviving patients 903 (range, 150-1955) days. The cumulative incidence (CI) of engraftment, acute graft-versus-host disease (GVHD) grade II to IV, and moderate/severe chronic GVHD was 92%, 17%, and 15%, respectively. The 4-year CI of transplant-related mortality (TRM) and relapse was 20% and 24%, respectively. Four-year survival for remission patients was 72% (74% versus 67% for

Original language	English
Pages (from-to)	1243-1249
Number of pages	7
Journal	Biology of Blood and Marrow Transplantation
Volume	24
Issue number	6
DOIs	https://doi.org/10.1016/j.bbmt.2018.01.031
Publication status	Published - 2018

Keywords

busulfan
cyclophosphamide
cyclosporine
fludarabine
mycophenolic acid
thiotepa, acute graft versus host disease
acute myeloid leukemia
adolescent
adult
aged
Article
bone marrow transplantation
cancer survival
chronic graft versus host disease
disease free survival
disease severity
engraftment
female
follow up
haploidentical transplantation
human
incidence
leukemia relapse
leukemia remission
major clinical study
male
mortality
myeloablative conditioning
overall survival
retrospective study

Access to Document

10.1016/j.bbmt.2018.01.031

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85042846121&doi=10.1016%2fj.bbmt.2018.01.031&partnerID=40&md5=e7b6cb5658e0a6ce842cde8a018aa7d6

Cite this

Chiusolo, P., Bug, G., Olivieri, A., Brune, M., Mordini, N., Alessandrino, P. E., Dominietto, A., Raiola, A. M., Di Grazia, C., Gualandi, F., Van Lint, M. T., Ferrara, F., Finizio, O., Angelucci, E., & Bacigalupo, A. (2018). A Modified Post-Transplant Cyclophosphamide Regimen, for Unmanipulated Haploidentical Marrow Transplantation, in Acute Myeloid Leukemia: A Multicenter Study. Biology of Blood and Marrow Transplantation, 24(6), 1243-1249. https://doi.org/10.1016/j.bbmt.2018.01.031

Chiusolo, P, Bug, G, Olivieri, A, Brune, M, Mordini, N, Alessandrino, PE, Dominietto, A, Raiola, AM, Di Grazia, C, Gualandi, F, Van Lint, MT, Ferrara, F, Finizio, O, Angelucci, E & Bacigalupo, A 2018, 'A Modified Post-Transplant Cyclophosphamide Regimen, for Unmanipulated Haploidentical Marrow Transplantation, in Acute Myeloid Leukemia: A Multicenter Study', Biology of Blood and Marrow Transplantation, vol. 24, no. 6, pp. 1243-1249. https://doi.org/10.1016/j.bbmt.2018.01.031

@article{c8656c4b3f9f4234b7c7b74c3dd2e9aa,

title = "A Modified Post-Transplant Cyclophosphamide Regimen, for Unmanipulated Haploidentical Marrow Transplantation, in Acute Myeloid Leukemia: A Multicenter Study",

abstract = "We report a modified post-transplant cyclophosphamide (PT-CY) regimen, for unmanipulated haploidentical marrow transplants, in 150 patients with acute myeloid leukemia (AML). All patients received a myeloablative regimen, cyclosporine A (CsA) on day 0, mycophenolate on day +1, and PT-CY 50 mg/kg on days +3 and +5. The median age was 51 (range, 17–74) years, 51 (34%) patients had active disease at transplant, and the median follow-up of surviving patients 903 (range, 150-1955) days. The cumulative incidence (CI) of engraftment, acute graft-versus-host disease (GVHD) grade II to IV, and moderate/severe chronic GVHD was 92%, 17%, and 15%, respectively. The 4-year CI of transplant-related mortality (TRM) and relapse was 20% and 24%, respectively. Four-year survival for remission patients was 72% (74% versus 67% for ",

keywords = "busulfan, cyclophosphamide, cyclosporine, fludarabine, mycophenolic acid, thiotepa, acute graft versus host disease, acute myeloid leukemia, adolescent, adult, aged, Article, bone marrow transplantation, cancer survival, chronic graft versus host disease, disease free survival, disease severity, engraftment, female, follow up, haploidentical transplantation, human, incidence, leukemia relapse, leukemia remission, major clinical study, male, mortality, myeloablative conditioning, overall survival, retrospective study",

author = "P. Chiusolo and G. Bug and A. Olivieri and M. Brune and N. Mordini and P.E. Alessandrino and A. Dominietto and A.M. Raiola and {Di Grazia}, C. and F. Gualandi and {Van Lint}, M.T. and F. Ferrara and O. Finizio and E. Angelucci and A. Bacigalupo",

note = "cited By 5",

year = "2018",

doi = "10.1016/j.bbmt.2018.01.031",

language = "English",

volume = "24",

pages = "1243--1249",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1083-8791",

publisher = "Elsevier Inc.",

number = "6",

}

TY - JOUR

T1 - A Modified Post-Transplant Cyclophosphamide Regimen, for Unmanipulated Haploidentical Marrow Transplantation, in Acute Myeloid Leukemia: A Multicenter Study

AU - Chiusolo, P.

AU - Bug, G.

AU - Olivieri, A.

AU - Brune, M.

AU - Mordini, N.

AU - Alessandrino, P.E.

AU - Dominietto, A.

AU - Raiola, A.M.

AU - Di Grazia, C.

AU - Gualandi, F.

AU - Van Lint, M.T.

AU - Ferrara, F.

AU - Finizio, O.

AU - Angelucci, E.

AU - Bacigalupo, A.

N1 - cited By 5

PY - 2018

Y1 - 2018

N2 - We report a modified post-transplant cyclophosphamide (PT-CY) regimen, for unmanipulated haploidentical marrow transplants, in 150 patients with acute myeloid leukemia (AML). All patients received a myeloablative regimen, cyclosporine A (CsA) on day 0, mycophenolate on day +1, and PT-CY 50 mg/kg on days +3 and +5. The median age was 51 (range, 17–74) years, 51 (34%) patients had active disease at transplant, and the median follow-up of surviving patients 903 (range, 150-1955) days. The cumulative incidence (CI) of engraftment, acute graft-versus-host disease (GVHD) grade II to IV, and moderate/severe chronic GVHD was 92%, 17%, and 15%, respectively. The 4-year CI of transplant-related mortality (TRM) and relapse was 20% and 24%, respectively. Four-year survival for remission patients was 72% (74% versus 67% for

AB - We report a modified post-transplant cyclophosphamide (PT-CY) regimen, for unmanipulated haploidentical marrow transplants, in 150 patients with acute myeloid leukemia (AML). All patients received a myeloablative regimen, cyclosporine A (CsA) on day 0, mycophenolate on day +1, and PT-CY 50 mg/kg on days +3 and +5. The median age was 51 (range, 17–74) years, 51 (34%) patients had active disease at transplant, and the median follow-up of surviving patients 903 (range, 150-1955) days. The cumulative incidence (CI) of engraftment, acute graft-versus-host disease (GVHD) grade II to IV, and moderate/severe chronic GVHD was 92%, 17%, and 15%, respectively. The 4-year CI of transplant-related mortality (TRM) and relapse was 20% and 24%, respectively. Four-year survival for remission patients was 72% (74% versus 67% for

KW - busulfan

KW - cyclophosphamide

KW - cyclosporine

KW - fludarabine

KW - mycophenolic acid

KW - thiotepa, acute graft versus host disease

KW - acute myeloid leukemia

KW - adolescent

KW - adult

KW - aged

KW - Article

KW - bone marrow transplantation

KW - cancer survival

KW - chronic graft versus host disease

KW - disease free survival

KW - disease severity

KW - engraftment

KW - female

KW - follow up

KW - haploidentical transplantation

KW - human

KW - incidence

KW - leukemia relapse

KW - leukemia remission

KW - major clinical study

KW - male

KW - mortality

KW - myeloablative conditioning

KW - overall survival

KW - retrospective study

U2 - 10.1016/j.bbmt.2018.01.031

DO - 10.1016/j.bbmt.2018.01.031

M3 - Article

VL - 24

SP - 1243

EP - 1249

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 6

ER -

A Modified Post-Transplant Cyclophosphamide Regimen, for Unmanipulated Haploidentical Marrow Transplantation, in Acute Myeloid Leukemia: A Multicenter Study

Abstract

Keywords

Access to Document

Fingerprint

Cite this